Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q7RTV2

UPID:
GSTA5_HUMAN

ALTERNATIVE NAMES:
GST class-alpha member 5; Glutathione S-transferase A5-5

ALTERNATIVE UPACC:
Q7RTV2; Q5SZC2

BACKGROUND:
The enzyme Glutathione S-transferase A5, also known as GST class-alpha member 5 or Glutathione S-transferase A5-5, is integral to the body's defense system. It facilitates the conjugation of glutathione with harmful substances, thereby playing a pivotal role in the detoxification pathway and safeguarding cells from oxidative stress.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Glutathione S-transferase A5 offers a promising avenue for drug discovery and development. Its critical role in neutralizing toxins and combating oxidative stress underscores its therapeutic potential in preventing and treating diseases related to oxidative damage and toxicant exposure.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.